These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 14615373

  • 21. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T, Vandendries E.
    Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS.
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [Abstract] [Full Text] [Related]

  • 23. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
    Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM.
    Blood; 2001 Jan 15; 97(2):528-35. PubMed ID: 11154233
    [Abstract] [Full Text] [Related]

  • 24. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
    Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.
    Blood; 2003 May 01; 101(9):3641-7. PubMed ID: 12511412
    [Abstract] [Full Text] [Related]

  • 25. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 26. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM.
    Blood; 2008 May 01; 111(9):4813-6. PubMed ID: 18326813
    [Abstract] [Full Text] [Related]

  • 27. CD22-directed monoclonal antibody therapy for lymphoma.
    Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP.
    Semin Oncol; 2003 Aug 01; 30(4):457-64. PubMed ID: 12939714
    [Abstract] [Full Text] [Related]

  • 28. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I.
    Int J Cancer; 1999 Mar 31; 81(1):148-55. PubMed ID: 10077166
    [Abstract] [Full Text] [Related]

  • 29. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
    Lindén O, Hindorf C, Tennvall J, Segrén S, Wingardh K, Strand SE.
    Cancer; 2002 Feb 15; 94(4 Suppl):1270-4. PubMed ID: 11877756
    [Abstract] [Full Text] [Related]

  • 30. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2004 Apr 15; 10(8):2868-78. PubMed ID: 15102696
    [Abstract] [Full Text] [Related]

  • 31. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L, O'Donnell RT, Tuscano JM.
    BioDrugs; 2013 Aug 15; 27(4):293-304. PubMed ID: 23696252
    [Abstract] [Full Text] [Related]

  • 32. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.
    Mol Cancer Ther; 2013 Jul 15; 12(7):1255-65. PubMed ID: 23598530
    [Abstract] [Full Text] [Related]

  • 33. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
    Weber T, Mavratzas A, Kiesgen S, Haase S, Bötticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J.
    J Immunol Res; 2015 Jul 15; 2015():561814. PubMed ID: 26605343
    [Abstract] [Full Text] [Related]

  • 34. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
    Leung SO, Shevitz J, Pellegrini MC, Dion AS, Shih LB, Goldenberg DM, Hansen HJ.
    Hybridoma; 1994 Dec 15; 13(6):469-76. PubMed ID: 7737671
    [Abstract] [Full Text] [Related]

  • 35. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
    Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, Kunz A, Hamann PR, Sridharan A, Jones S, Discafani C, Damle NK.
    Int J Oncol; 2006 Mar 15; 28(3):675-84. PubMed ID: 16465373
    [Abstract] [Full Text] [Related]

  • 36. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC.
    Cancer Biother Radiopharm; 2003 Aug 15; 18(4):525-33. PubMed ID: 14503946
    [Abstract] [Full Text] [Related]

  • 37. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.
    Newton DL, Ryback SM.
    Expert Opin Biol Ther; 2001 Nov 15; 1(6):995-1003. PubMed ID: 11728231
    [Abstract] [Full Text] [Related]

  • 38. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.
    Clin Cancer Res; 2008 Oct 01; 14(19):6154-60. PubMed ID: 18829494
    [Abstract] [Full Text] [Related]

  • 39. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 40. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A, O'Brien SM.
    Drugs Today (Barc); 2017 Dec 04; 53(12):653-665. PubMed ID: 29517084
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.